A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Plain-language summary

This is a prospective, exploratory, non-registration, multi-center clinical study to evaluate the efficacy and safety of becotatug vedotin (EGFR-ADC) combined with putlimab and radiotherapy in the perioperative treatment of locally advanced resectable head and neck squamous cell carcinoma (HNSCC). \*\*Neoadjuvant Phase\*\* (3-week cycle, 2 cycles): * Putlimab (HX008): 200 mg, Q3W, D1, IV * Becotatug vedotin (MRG003): 2.0 mg/kg, Q3W, D1, IV \*\*Adjuvant/Maintenance Phase:\*\* Surgery within 2-4 weeks post-neoadjuvant; surgical approach at investigator discretion. \*\*Group A (Postoperative pCR):\*\* * Putlimab (HX008): 200 mg, Q3W, D1, IV, up to 1 year * Adjuvant RT: 40 Gy/5 weeks \*\*Group B (Postoperative MPR):\*\* * Putlimab (HX008): 200 mg, Q3W, D1, IV, up to 1 year * Adjuvant RT: 50 Gy/5 weeks \*\*Group C (Postoperative Partial/No Response):\*\* * Low-risk (no extracapsular nodal extension \[ENE\] and negative margins): Putlimab 200 mg Q3W (up to 1 year) + RT 60 Gy/6 weeks * High-risk (ENE and/or positive margins): Putlimab 200 mg Q3W (up to 1 year) + RT 60-66 Gy/6-6.6 weeks + Cisplatin 60 mg/m², Q3W, D1, IV, for 2 cycles RT timing, field, and fractionation may be adjusted by investigators based on individual disease status. Imaging assessment every 2 cycles (±7 days) until disease recurrence, initiation of new anti-tumor therapy, withdrawal of informed consent, death, or up to 21 cycles, whichever occurs first. Additional imaging may be performed at any time if clinically indicated.

Who can participate

What they're measuring

Trial details